Overview
Amoebiasis due to Entamoeba histolytica is an infectious parasitic disease caused by the protozoan parasite Entamoeba histolytica. It is not a genetic disorder but rather an acquired infection transmitted through the fecal-oral route, typically via contaminated water or food. The disease is most prevalent in tropical and subtropical regions with poor sanitation. Approximately 90% of infections are asymptomatic, but the parasite can cause significant illness when it invades the intestinal wall or spreads to other organs. The disease primarily affects the gastrointestinal system, most commonly the colon, where it causes amoebic colitis characterized by bloody diarrhea (amoebic dysentery), abdominal pain, cramping, and tenderness. The parasite can erode through the intestinal mucosa, forming characteristic flask-shaped ulcers. In more severe cases, Entamoeba histolytica can spread hematogenously to the liver, causing amoebic liver abscess, which presents with right upper quadrant pain, fever, and hepatomegaly. Less commonly, the infection can disseminate to the lungs, brain, or other organs, leading to potentially life-threatening complications including amoebic lung abscess, cerebral amoebiasis, or cutaneous amoebiasis. Treatment depends on the clinical presentation. Invasive amoebiasis (symptomatic intestinal disease or extraintestinal disease) is treated with metronidazole or tinidazole as tissue-active agents, followed by a luminal agent such as paromomycin or diloxanide furoate to eliminate cysts remaining in the intestine. Asymptomatic carriers harboring cysts should also be treated with a luminal agent to prevent transmission and potential future invasive disease. Large liver abscesses may occasionally require percutaneous drainage. With appropriate treatment, the prognosis is generally good, though fulminant colitis and ruptured liver abscess carry significant mortality. Prevention relies on improved sanitation, safe water supply, and proper food hygiene.
Clinical phenotype terms— hover any for plain English:
Variable
Can begin at different ages, from infancy through adulthood
Treatments
No FDA-approved treatments are currently listed for Amoebiasis due to Entamoeba histolytica.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Amoebiasis due to Entamoeba histolytica at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Amoebiasis due to Entamoeba histolytica.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Amoebiasis due to Entamoeba histolytica.
Community
No community posts yet. Be the first to share your experience with Amoebiasis due to Entamoeba histolytica.
Start the conversation →Latest news about Amoebiasis due to Entamoeba histolytica
No recent news articles for Amoebiasis due to Entamoeba histolytica.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Amoebiasis due to Entamoeba histolytica
What is Amoebiasis due to Entamoeba histolytica?
Amoebiasis due to Entamoeba histolytica is an infectious parasitic disease caused by the protozoan parasite Entamoeba histolytica. It is not a genetic disorder but rather an acquired infection transmitted through the fecal-oral route, typically via contaminated water or food. The disease is most prevalent in tropical and subtropical regions with poor sanitation. Approximately 90% of infections are asymptomatic, but the parasite can cause significant illness when it invades the intestinal wall or spreads to other organs. The disease primarily affects the gastrointestinal system, most commonly